Matinas BioPharma | Investor Presentation Deck | 28 slides · page 22 of 28
The slide compares Matinas' PS-NP technology stability (17 weeks) against Moderna (30 days) and Pfizer/BioNTech (10 weeks) at refrigerated temperatures.
Pitch deck · traction · show_traction · dense density
Slide locked Sign in to view
Slide schematic 6/6
chart 1/1 image 1/1 list 1/1 source-note 2/2 title 1/1
Components 6
bar-grouped illustration bullet source-note source-note headline
Tools 1
Metrics 0
∅
No metrics
No metric insight is anchored to this slide.
Frameworks 0
∅
No frameworks
No framework match is anchored to this slide.